Repertoire Immune Medicines has entered into a strategic collaboration with Eli Lilly and Company to develop tolerizing therapies for multiple autoimmune diseases, the companies said on Wednesday.
The collaboration will combine Repertoire’s DECODE™ platform, which is designed to discover and develop T cell–targeted immune medicines, with Lilly’s capabilities in clinical development, manufacturing, regulatory affairs, and commercialisation. The goal is to develop therapies that restore immune balance and enable durable disease remission without the broad immune suppression associated with many current autoimmune treatments.
Under the agreement, Repertoire will lead research and development activities through the nomination of development candidates. Lilly will take over responsibility from that stage onward, including late-stage development and global commercialisation of any therapies emerging from the collaboration.
Repertoire will use its DECODE™ T cell receptor–epitope discovery platform to identify and advance candidates designed to selectively tolerise disease-driving immune responses, addressing the underlying causes of immune dysregulation in autoimmune conditions.
As part of the deal, Repertoire will receive an upfront payment of $85 million and is eligible to receive up to $1.84 billion in development and commercial milestone payments. The agreement also includes tiered royalties on net sales of any approved products.
The partnership expands Repertoire’s pipeline of partnered tolerizing therapies and strengthens Lilly’s immunology portfolio, reflecting continued industry focus on next-generation approaches to treating autoimmune diseases by precisely modulating the immune system rather than suppressing it broadly.
